Capstone Therapeutics Announces Update to Timing of Release of Final Results From AZX100 Phase 2a Pilot Clinical Trial in Surgical (Trocar Site) Scarring

TEMPE, Ariz., April 4, 2011 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) (the “Company”) today announced an update to the reporting schedule for twelve-month results from its AZX100 Phase 2a pilot clinical trial in surgical (trocar site) scarring.